Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Advanced Thymoma and Thymic Carcinoma

  • Thymoma
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Although thymic epithelial tumors are rare, they are relatively common among neoplasms of the anterior superior mediastinum. They usually exhibit indolent behavior, but do have the capacity to invade surrounding structures and metastasize to distant sites. Thymic carcinomas are rare, but are highly aggressive tumors that are associated with a poor prognosis. The mainstay of therapy is complete surgical resection. Locally advanced thymoma and thymic carcinoma require a multimodality treatment approach with a combination of surgery, chemotherapy, and radiation therapy to decrease the chances of recurrence and improve survival. The risk of disease recurrence lasts for a number of years after completion of primary therapy. A majority of cases of recurrent disease present as pleural recurrences. Once again, surgical resection of recurrent disease represents the cornerstone of successful therapy and is critical to long-term survival. In recent years, a better understanding of the biologic basis of thymic epithelial tumors has led to the emergence of targeted therapy directed against this malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy of invasive thymoma. J Clin Oncol 1990; 8(8): 1419–1423.

    PubMed  CAS  Google Scholar 

  2. Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg 2003; 125(2): 434–467. doi:10.1067/mtc.2003.133.

    Article  PubMed  Google Scholar 

  3. Johnson SB, Eng TY, Giaccone G, Thomas CR. Thymoma: Update for the new millennium. The Oncologist 2001; 6: 239–246. doi:10.1634/theoncologist.6-3-239.

    Article  PubMed  CAS  Google Scholar 

  4. Masaoka A, Mondem Y, Nakahara K, et al.: Follow-up study of thymoma with special reference to their clinical stages. Cancer 1981; 48: 2485–92. doi:10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R

    Google Scholar 

  5. Masaoka A, Yamakawa Y, Niwa H, et al. Thymectomy and malignancy. Eur J Cardiothoracic Surg 1994; 8: 251–253. doi:10.1016/1010-7940(94)90155-4.

    Article  CAS  Google Scholar 

  6. Okumura M, Onta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624–32. doi:10.1002/cncr.10226.

    Article  PubMed  Google Scholar 

  7. Suster S, Moran CA. Histologic classification of thymoma: the World Health Organization and beyond. Hematol Oncol Clin N Am 2008;22:381–392. doi:10.1016/j.hoc.2008.03.001.

    Article  Google Scholar 

  8. Lopez-Cano M, Ponseti-Bosch JM, Espin-Basany E, et al. Clinical and pathologic predictors of outcome in thymoma-associated myasthenia gravis. Ann Thorac Surg 2003; 76: 1643–1649. doi:10.1016/S0003-4975(03)01139-1.

    Article  PubMed  Google Scholar 

  9. Morgenthaler TI, Brown LR, Colby TV, et al. Thymoma. Mayo Clin Proc 1993; 68: 1110–1123.

    PubMed  CAS  Google Scholar 

  10. Suadjian JV, Enriquez P, Siverstein MN, et al. The spectrum of diseases associated with thymoma: coincidence or syndrome? Arch Intern Med 1974; 134: 374–379. doi:10.1001/archinte.134.2.374.

    Article  Google Scholar 

  11. Tormoehlen LM, Pascuzzi RM. Thymoma, myastenia gravis, and other paraneoplastic syndromes. Hematol Oncol Clin North Am 2008;22(3):509–526. doi:10.1016/j.hoc.2008.03.004.

    Article  PubMed  Google Scholar 

  12. Wright CD. Management of Thymomas. Critical Reviews in Oncology/Hematology 2008; 65: 109–120. doi:10.1016/j.critrevonc.2007.04.005.

    Article  Google Scholar 

  13. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 2003; 76: 878–85. doi:10.1016/S0003-4975(03)00555-1.

    Article  PubMed  Google Scholar 

  14. Giaccone G, Wilnik H, Paul MA, van der Valk P. Systemic treatment of malignant thymoma. Am J Clin Oncol 2006; 29: 336–344. doi:10.1097/01.coc.0000227481.36109.e7.

    Article  PubMed  Google Scholar 

  15. Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008; 85 (2): 385–389. doi:10.1016/j.athoracsur.2007.08.051.

    Article  PubMed  Google Scholar 

  16. Haniuda M, Morimoto M, Nishimura H, e al. Adjuvant radiotherapy after complete resection of thymoma. Ann Thorac Surg 1992; 54: 311–315.

    Article  PubMed  CAS  Google Scholar 

  17. Loehrer PJ, Kim KM, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: Final results of an Intergroup Trial. J Clin Oncol. 1994; 12: 1164–1168.

    PubMed  Google Scholar 

  18. Fornasiesro A, Daniele O, Ghiotto C, et al.: Chemotherapy for invasive thymoma: A 13 year experience. Cancer 1991; 68:30–33. doi:10.1002/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4

    Google Scholar 

  19. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and Etoposide combination chemotherapy for locally advanced or metastatic thymoma: A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14: 814–820.

    PubMed  CAS  Google Scholar 

  20. Loehrer PJ, Jiroutek M, Aisner S, et al.: Combined Etoposide, ifosfamide and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. An Intergroup Trial. Cancer 2001; 91: 2010–2015. doi:10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2

    Google Scholar 

  21. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary Treatment for Advanced Invasive Thymoma with Cisplatin, Doxorubicin, and Methylprednisolone. J Thorac Oncol 2007; 2: 73–78. doi:10.1097/JTO.0b013e31802bafc8.

    Article  PubMed  Google Scholar 

  22. Lemma GL, Loehrer PJ, Lee JW, et al.: A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26 [Abstract 8018]

  23. Hejna M, Haberl I, Raderer M. Nonsurgical management of malignant thymoma. Cancer 1999; 85: 1871–1884.

    PubMed  CAS  Google Scholar 

  24. Bonomi PD, Finkelstein D, Aisner S, Ettinger D. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993; 16(4):342–345. doi:10.1097/00000421-199308000-00014.

    Article  PubMed  CAS  Google Scholar 

  25. Henley JD, Cummings OW, Loehrer PJ Sr. Tyrosine kinase receptor expression in thymomas. J Cancer Res Clin Oncol. 2004; 130: 222–224. doi:10.1007/s00432-004-0545-z.

    Article  PubMed  CAS  Google Scholar 

  26. Meister M, Schirmacher P, Dienemann H, et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett. 2007; 248: 186–191. doi:10.1016/j.canlet.2006.07.003.

    Article  PubMed  CAS  Google Scholar 

  27. Nakagawa K, Matsuno Y, Kunitoh H, et al. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. Chest 2005; 128: 140–144. doi:10.1378/chest.128.1.140.

    Article  PubMed  CAS  Google Scholar 

  28. Farina G, Garassino MC, Gambacorta M, et al. Response of thymoma to cetuximab. Lancet Oncol 2007; 8: 449–450. doi:10.1016/S1470-2045(07)70141-9.

    Article  PubMed  Google Scholar 

  29. Palmieri G, Marino M, Salvatore M, et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007; 12: 757–761. doi:10.2741/2098.

    Article  PubMed  CAS  Google Scholar 

  30. Kurup A, Burns M, Dropcho S, et al.: Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005, ASCO Annual Meeting Proceedings; 23: [Abstract 7068]

  31. Bedano PM, Perkins S, Burns M, et al.: A phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 19087]

  32. Strobel P, Hautmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Eng J Med 2004; 350: 2625–2626. doi:10.1056/NEJM200406173502523.

    Article  Google Scholar 

  33. Giaccone G, Smit EF, van Groeningen C, Hogedoorn PC. Phase II study of imatinib in patients with WHO B3 and C thymomas. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 14665]

  34. Salter JT, Lewis D, Yiannoutsos C, et al.: Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008, ASCO Annual Meeting Proceedings; 26: [Abstract 8116]

  35. Chuah C, Lim TH, Lim AST, et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006; 24: e56-e58. doi:10.1200/JCO.2006.08.8963.

    Article  PubMed  Google Scholar 

  36. Suster S, Rosai J: Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer 1991; 67: 1025–1032. doi:10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F

    Google Scholar 

  37. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. Int J Radiat Oncol Biol Phys 2004; 59: 654–664. doi:10.1016/j.ijrobp.2003.11.021.

    PubMed  Google Scholar 

  38. Penzel R, Hoegel J, Schmitz W, et al. Clusters of chromosomal imbalances in thymic epithelial tumors are associated with the WHO classification and the staging system according to Masaoka. Int J Cancer 2003; 105: 494–498. doi:10.1002/ijc.11101.

    Article  PubMed  CAS  Google Scholar 

  39. Inoue M, Starostik P, Zettl A, et al. Correlating genetic abnormalities with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res 2003; 63: 3708–3715.

    PubMed  CAS  Google Scholar 

  40. WeideLG, Ulbright TM, Loehrer PJ Sr, Williams SD: Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. Cancer 1993;71(4): 1219–1223. doi:10.1002/1097-0142(19930215)71:4<1219::AID-CNCR2820710408>3.0.CO;2-B

  41. Lucchi M, Mussi A, Basolo F, et al. The multimodality treatment of thymic carcinoma. Eur J Cardiothorac Surg 2001; 19: 566–569. doi:10.1016/S1010-7940(01)00666-2.

    Article  PubMed  CAS  Google Scholar 

  42. Magois E, Guigay J, Blancard PS, et al. Multimodal treatment of thymic carcinoma: Report of nine cases. Lung Cancer 2008; 59: 126–132. doi:10.1016/j.lungcan.2007.05.016.

    Article  PubMed  Google Scholar 

  43. Hernandez-Ilizaliturri FJ, Tan D, Cipolla D, et al. (2004) Multimodality therapy for thymic carcinoma (TCA) Results of a 30-year single-institution experience. Am J Clin Oncol 27: 68–72. doi:10.1097/01.coc.0000046301.83671.09.

    Article  PubMed  CAS  Google Scholar 

  44. Huang J, Rizk N, Park B, et al.: Recent clinical experience with multimodality therapy in thymic carcinoma. J Clin Oncol 2007, ASCO Annual Meeting Proceedings; 25: [Abstract 18003]

  45. Ciccone AM, Rendina EA. Treatment of Recurrent Thymic Tumors. Semin Thorac Cardiovasc Surg 2005; 17: 27–31. doi:10.1053/j.semtcvs.2004.12.004.

    Article  PubMed  Google Scholar 

  46. Loehrer PJ, Wang W, Johnson DH, Ettinger DS. Octreotide alone or with Prednisone in Patients with Advanced Thymoma and Thymic Carcinoma. An Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol 2004; 22: 293–299. doi:10.1200/JCO.2004.02.047.

    Article  PubMed  CAS  Google Scholar 

  47. Loehrer PJ, Yiannoutsos CT, Dropcho S, et al.: A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006, ASCO Annual Meeting Proceedings; 24: [Abstract 7079]

  48. Umemura S, Segawa Y, Fujiwara K, et al. A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. Jpn J Clin Oncol 2002;32(7):262–265. doi:10.1093/jjco/hyf059.

    Article  PubMed  Google Scholar 

  49. Oguri T, Achiwa H, Kato D, et al. Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy 2004;50:279–282. doi:10.1159/000082626.

    Article  PubMed  CAS  Google Scholar 

  50. Lucchi M, Basolo F, Mussi A. Surgical treatment of pleural recurrence from thymoma. Eur J Cardiothorac Surg 2008; 33: 707–711. doi:10.1016/j.ejcts.2008.01.015.

    Article  PubMed  Google Scholar 

  51. Sugie C, Shibamoto Y, Ikeya-Hashizuma C, et al. Invasive thymoma: postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. J Thorac Oncol 2008; 3: 75–81. doi:10.1097/JTO.0b013e31815e8b73.

    Article  PubMed  Google Scholar 

  52. DeBree E, van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002; 121: 480–487. doi:10.1378/chest.121.2.480.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Branch, National Cancer Institute, Bethesda, MD, USA

    Arun Rajan MD & Giuseppe Giaccone MD, PhD

Authors
  1. Arun Rajan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Giaccone MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Giaccone MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rajan, A., Giaccone, G. Treatment of Advanced Thymoma and Thymic Carcinoma. Curr. Treat. Options in Oncol. 9, 277–287 (2008). https://doi.org/10.1007/s11864-009-0083-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0083-7

Keywords

Search

Navigation